The study of sugars is complicated and there are relatively few agents for their study. Standard current practice is to use lectins or biochemical separations with liquid chromatography and mass spectrometry. All of these methods are severely limited becuase they are time consuming, expensive, and require technical expertise. Thses methods also require relatively large sample size which limists their value in point-of-care setting.We envision creating a small chip with an array of different elements spotted on it. Each would have differential and discriminatory binding to sugars. A sample from a tumor or other cells would be applied to the chip to create a quantitative pattern of binding. An alogorithm would be applied to the data to crease a diagnosis. The assay would be inexpensive, orbust and fast. Such an analysis can not be done in a clinically relevant way with existing technology.this technology can also be used to study the GlycoSignatures or recombinant glycoconjugate drugs. Currently, the market of these drugs in the U.S. alone is approximately $25-30 Billion/year. In all of these cases the glycosylation status of these drugs is verified by HPLC and MS methods which, as mentioned above, are tedious. We envision our technology being used for rapid analysis of GlycoSignatures on these drugs.
|Original language||English (US)|
|State||Published - Jun 2 2006|